文献速递胸部肿瘤放疗

同步放化疗的非小细胞肺癌患者治疗期间淋巴细胞减少风险与治疗结局及巩固免疫治疗疗效相关

Risk of on-treatment lymphopenia is associated with treatment outcome and efficacy of consolidation immunotherapy in patients with non-small cell lung cancer treated with concurrent chemoradiotherapy.
PubMed 文献 · Radiother Oncol · 2023-09-30

研究纳入517例接受同步放化疗的局部晚期非小细胞肺癌患者,用肺、心脏和全身平均剂量计算免疫细胞有效剂量(EDIC),结合放疗前绝对淋巴细胞计数(ALC)分组。EDIC≥2.89 Gy且放疗前ALC<2.03×10^9细胞/L的高危组严重淋巴细胞减少发生率为90.1%,且该组未能从巩固免疫治疗中获得显著生存获益。

要点

  • EDIC≥2.89 Gy且放疗前ALC<2.03×10^9细胞/L定义为高危组,严重淋巴细胞减少发生率为90.1%。
  • 低危组严重淋巴细胞减少发生率为52.3%,中间危组为77.1%,三组比较P<0.001。
  • 巩固免疫治疗在低危和中间危组显示显著生存获益,高危组未显示显著获益。

核心结论

  • EDIC与放疗前ALC的组合可预测严重淋巴细胞减少、复发和生存,可能作为巩固免疫治疗的生物标志物。

研究设计与样本

  • 研究纳入517例接受同步放化疗的局部晚期非小细胞肺癌患者,EDIC通过肺、心脏和全身平均剂量计算,按EDIC和放疗前ALC高低分组分析其与放射性淋巴细胞减少及生存结局的相关性。

主要发现

  • 195例患者(37.7%)接受了巩固免疫治疗。
  • 预测严重淋巴细胞减少的EDIC和放疗前ALC截断值分别为2.89 Gy和2.03×10^9细胞/L。
  • 高危组(EDIC≥2.89 Gy且放疗前ALC<2.03×10^9细胞/L)、中间危组和低危组(EDIC<2.89 Gy且放疗前ALC≥2.03×10^9细胞/L)的放疗期间严重淋巴细胞减少发生率分别为90.1%、77.1%和52.3%(P<0.001)。
  • 风险分组可独立预测无进展生存(P<0.001)和总生存(P<0.001)。
  • 高危组局部区域复发和远处复发发生率更高(P<0.001)。

关键数值与推荐

  • 高危组定义:EDIC≥2.89 Gy且放疗前ALC<2.03×10^9细胞/L。
  • 低危组定义:EDIC<2.89 Gy且放疗前ALC≥2.03×10^9细胞/L。
  • 中间危组定义:其余患者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: The ability of the effective dose to immune cells (EDIC) and the pre-radiotherapy (RT) absolute lymphocyte count (ALC) to predict lymphopenia during RT, treatment outcomes, and efficacy of consolidation immunotherapy in patients with locally advanced non-small cell lung cancer was investigated. METHODS AND MATERIALS: Among 517 patients treated with concurrent chemoradiotherapy, EDIC was calculated using the mean doses to the lungs, heart, and total body. The patients were grouped according to high and low EDIC and pre-RT ALC, and the correlations with radiation-induced lymphopenia and survival outcomes were determined. RESULTS: Altogether, 195 patients (37.7%) received consolidation immunotherapy. The cutoff values of EDIC and pre-RT ALC for predicting severe lymphopenia were 2.89 Gy and 2.03 × 109 cells/L, respectively. The high-risk group was defined as EDIC ≥ 2.89 Gy and pre-RT ALC < 2.03 × 109 cells/L, while the low-risk group as EDIC < 2.89 Gy and pre-RT ALC ≥ 2.03 × 109 cells/L, and the rest of the patients as the intermediate-risk group. The incidences of severe lymphopenia during RT in the high-, intermediate-, and low-risk groups were 90.1%, 77.1%, and 52.3%, respectively (P < 0.001). The risk groups could independently predict both progression-free (P < 0.001) and overall survival (P < 0.001). The high-risk group showed a higher incidence of locoregional and distant recurrence (P < 0.001). Consolidation immunotherapy showed significant survival benefit in the low- and intermediate-risk groups but not in the high-risk group. CONCLUSIONS: The combination of EDIC and pre-RT ALC predicted severe lymphopenia, recurrence, and survival. It may potentially serve as a biomarker for consolidation immunotherapy.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Yang G, Yoon HI, Lee J, et al. Risk of on-treatment lymphopenia is associated with treatment outcome and efficacy of consolidation immunotherapy in patients with non-small cell lung cancer treated with concurrent chemoradiotherapy. Radiother Oncol. 2023. PMID: 37783291. doi:10.1016/j.radonc.2023.109934

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。